Shrinks In Sneakers

Category: Uncategorized

  • Crush Long Hours: The Ultimate Hack for Demanding Jobs!

    Crush Long Hours: The Ultimate Hack for Demanding Jobs!

    It seems like ADHD medication is following me this week—or maybe it’s the law of attraction at work as I keep coming across articles aligned with the key points I’ve been reflecting on recently.

    A recent Wall Street Journal article highlights the growing use of prescription stimulants like Adderall and Vyvanse among young investment bankers, helping them manage the grueling demands of 90-hour workweeks. While the prevalence of substances to enhance performance isn’t new (cocaine was once the drug of choice), it’s become much easier to obtain legal alternatives. A quick five-minute online questionnaire can now yield a prescription, no shady drug dealers required.

    The article centers on a young professional who, despite his own skepticism about having ADHD, found the medication transformative for surviving the intense pace of his job. Predictably, dependency followed.

    This isn’t an isolated issue, nor is it exclusive to investment banking. We’ve seen a marked increase in adult ADHD diagnoses, likely tied to the expansion of telehealth and more relaxed prescribing practices.

    While the article rightly calls for reevaluating workplace expectations and support systems, let’s be honest—this phenomenon isn’t going anywhere soon. The stakes are too high: major profits for companies and career-defining opportunities for individuals.

    We need to acknowledge this for what it really is: the use of performance-enhancing drugs (PEDs) to gain an edge in professional life. In many ways, it’s no different from using steroids in sports. Maybe the real question isn’t how to stop it, but whether we should allow informed adults to use PEDs under careful medical supervision.

    I’ll let you all weigh in on that one.

    Cheers,
    Dr. G

    LInk: https://www.wsj.com/finance/banking/young-banker-finance-adhd-medication-adderall-d578a16f

  • APA Updates Guidance on Borderline Personality Disorder: What Clinicians Need to Know

    APA Updates Guidance on Borderline Personality Disorder: What Clinicians Need to Know

    Borderline Personality Disorder (BPD) is one of the most misunderstood and challenging conditions in psychiatric practice. It’s a topic I’m particularly passionate about, as patients with BPD are frequently misdiagnosed, and many clinicians hesitate to assign the diagnosis due to stigma or uncertainty. This reluctance often leads to suboptimal care, including the overuse of multiple medication classes without clear benefit. In response to these challenges, the American Psychiatric Association (APA) has recently updated its guidelines on BPD, providing a more comprehensive framework to enhance diagnosis and treatment. This update represents a significant step forward in improving care for a condition that has long been underserved.

    1. Diagnosis and Early Detection

    The updated guidance emphasizes the importance of early identification of BPD symptoms, particularly in adolescence and early adulthood. It encourages clinicians to use structured diagnostic tools alongside clinical interviews to reduce misdiagnosis and stigma.

    2. Therapeutic Approaches

    Evidence-based psychotherapies remain the cornerstone of BPD treatment. Dialectical Behavior Therapy (DBT) continues to hold strong empirical support, but the APA has expanded its recommendations to include:

    • Mentalization-Based Therapy (MBT)
    • Transference-Focused Psychotherapy (TFP)
    • Good Psychiatric Management (GPM)

    The guidance highlights the importance of tailoring therapy to individual patient needs, with a focus on building trust and managing emotional dysregulation.

    3. Medications

    While no medications are FDA-approved specifically for BPD, the APA guidance underscores the role of pharmacotherapy in managing co-occurring conditions such as mood disorders, anxiety, and impulsivity. Clinicians are advised to take a cautious and evidence-based approach to prescribing, avoiding polypharmacy whenever possible.

    4. Stigma Reduction and Patient Advocacy

    The guidance calls for a shift in how clinicians, patients, and society perceive BPD. Educating patients and their families about the condition, normalizing treatment, and advocating for systemic support are crucial components.

    5. Integrative and Community-Based Care

    The APA emphasizes the need for multidisciplinary care teams and integrating care across settings. This includes collaboration with primary care providers, social services, and crisis intervention programs to ensure continuity of care.

    6. Focus on Outcomes and Recovery

    The updated guidance reflects a recovery-oriented approach, focusing on helping patients achieve long-term functional improvement and quality of life. Measuring treatment outcomes and adapting care plans accordingly are encouraged practices.

    Conclusion

    These updates highlight the APA’s commitment to improving outcomes for individuals living with BPD. By promoting evidence-based practices, reducing stigma, and advocating for patient-centered care, clinicians are better equipped to address the challenges associated with this condition.

    What do you think about these changes? How do you see them impacting your practice or care delivery?

  • ADHD in Later Life: A Surge in Diagnoses Among Older Americans

    ADHD in Later Life: A Surge in Diagnoses Among Older Americans

    🤣 What a perfect time for this article considering ADHD is my topic of choice this week.

    🧠 A nuanced debate surrounds the rise in ADHD diagnoses, particularly among adults. While underdiagnosis and increased awareness contribute to this trend, it’s not the sole explanation. ADHD, often linked to developmental delays, may require continued medication into adulthood for some individuals with persistent symptoms

    ➡️ However, the necessity for lifelong medication in all or most cases is questionable

    ➡️ The surge in first-time ADHD diagnoses among adults aged 30’s-40’s, often without prior documented history, raises important questions

    💡 While some cases may have been previously overlooked, it’s crucial to consider:

    ⚡ Co-occurring disorders like depression and anxiety, which can cause similar cognitive issues

    ⚡ Societal factors: Increasing demands for productivity and competitiveness in modern society

    ⚡ The potential misuse of performance-enhancing drugs in high-pressure environments

    💡 It’s essential to approach each case individually, considering both the benefits of treatment and the risks of overdiagnosis. A comprehensive evaluation, including assessment of co-existing conditions and life circumstances, is crucial for accurate diagnosis and appropriate treatment plans

    Link to NYT article: https://www.nytimes.com/2024/12/11/well/mind/adhd-diagnosis-older-middle-age.html

    #ADHD #ADHDawarness #ADHDtreatment #ADHDtips #ADHDlife #mentalhealth #mentalhealthmatters #mentalhealthishealth #psychiatry #psychiatrist #doctor #stimulants #stimulantmedication

  • How to Create a Routine for ADHD: A Step-by-Step Guide

    How to Create a Routine for ADHD: A Step-by-Step Guide

    Creating a structured routine is one of the most effective ways to manage ADHD symptoms. The goal is to provide consistency and reduce decision fatigue, which can make daily tasks feel overwhelming.

    Step 1: Assess Your Current Habits

    • Track your time: Spend a few days writing down how you currently spend your time. Identify patterns, distractions, and areas where you struggle with productivity.
    • Note energy levels: Pay attention to when you feel most focused and energetic, as this will help in scheduling demanding tasks during peak times.

    Step 2: Define Your Priorities

    • Identify the most important activities in your day (e.g., work, exercise, family time).
    • Rank these priorities, so you focus on what truly matters and avoid overloading your schedule.

    Step 3: Break Down Your Day

    • Morning Routine: Start the day with consistent habits like making your bed, brushing your teeth, and eating breakfast. Keep it simple to reduce stress.
    • Work/School Blocks: Break tasks into smaller chunks with scheduled breaks. For example, use the Pomodoro Technique (25 minutes of focused work followed by a 5-minute break).
    • Afternoon Wind-Down: Use this time for less mentally taxing tasks like errands or light chores.
    • Evening Routine: Establish a calming routine to prepare for bed, such as reading, meditating, or journaling.

    Step 4: Use Visual Aids and Tools

    • Calendars/Planners: Write down your schedule. Use color-coding for different types of tasks (e.g., green for work, blue for leisure).
    • Digital Apps: Tools like Google Calendar, Todoist, or Notion can send reminders and help you stay organized.
    • Visual Timers: Use timers or clocks to track tasks and breaks visually.

    Step 5: Set Alarms and Reminders

    • Set alarms for key transitions (e.g., starting work, eating lunch, or ending the workday).
    • Use apps like Habitica or Forest to gamify task completion and make sticking to your routine more fun.

    Step 6: Build Flexibility into Your Routine

    ADHD often brings spontaneity or unexpected distractions.

    • Leave buffer time between tasks to account for delays.
    • Prioritize your top 3 tasks each day, so even if you deviate, the essentials get done.

    Step 7: Simplify Transitions

    Transitioning between activities can be challenging with ADHD.

    • Use auditory or visual cues to signal it’s time to switch tasks.
    • Prepare for the next activity in advance (e.g., set out clothes for the gym or prep your workspace for the next day).

    Step 8: Keep Your Environment ADHD-Friendly

    • Declutter regularly to minimize distractions.
    • Use bins, labels, or baskets to keep essentials easily accessible.

    Step 9: Reflect and Adjust

    • At the end of each day or week, review your routine. What worked? What didn’t?
    • Be flexible and tweak your schedule to fit your needs and energy levels.

    Step 10: Start Small and Build Gradually

    • Focus on one or two parts of your routine at first, like improving your morning habits.
    • Celebrate small wins to build confidence and motivation.

    Example Routine:

    Morning:

    • 7:00 AM: Wake up and drink water
    • 7:15 AM: Quick workout or stretching
    • 7:30 AM: Shower and get dressed
    • 7:45 AM: Eat breakfast and review the day

    Work/School Blocks:

    • 9:00 AM – 12:00 PM: Focused work (Pomodoro cycles)
    • 12:00 PM – 1:00 PM: Lunch and light activity
    • 1:00 PM – 4:00 PM: Afternoon tasks (easier or creative work)

    Evening:

    • 6:00 PM: Dinner
    • 7:00 PM: Relaxation (reading, hobbies)
    • 9:00 PM: Prep for tomorrow (pack bag, set clothes out)
    • 10:00 PM: Lights out

  • Improving ADHD Symptoms Without Medication

    Improving ADHD Symptoms Without Medication

    Medication is a cornerstone of ADHD management, but combining it with complementary strategies can significantly enhance focus, organization, and overall functioning. This post offers a high-level overview of these approaches, setting the stage for a series of actionable, in-depth posts later this week.

    1. Establish a Routine

    Creating a structured daily routine provides predictability and reduces distractions. Use planners, calendars, or apps to break your day into manageable chunks with clear priorities.

    2. Practice Mindfulness and Meditation

    Mindfulness can improve attention regulation and emotional control. Apps like Headspace or Calm offer guided practices tailored to ADHD, helping you build focus over time.

    3. Exercise Regularly

    Aerobic exercise boosts dopamine and norepinephrine levels, enhancing focus and motivation. Aim for 30-60 minutes of activity daily, whether it’s running, swimming, or dancing.

    4. Improve Sleep Hygiene

    ADHD often disrupts sleep, which worsens symptoms. Establish a consistent bedtime, avoid screens before bed, and create a calming nighttime routine to promote better rest.

    5. Optimize Nutrition

    Balanced meals with protein, complex carbs, and omega-3 fatty acids can stabilize energy levels and improve concentration. Consider foods like salmon, eggs, nuts, and leafy greens.

    6. Break Tasks into Smaller Steps

    Large tasks can feel overwhelming. Break them down into smaller, manageable steps, and use tools like timers to focus on one step at a time (e.g., the Pomodoro Technique).

    7. Minimize Distractions

    Create an ADHD-friendly environment by limiting noise, clutter, and interruptions. Noise-canceling headphones and tidy workspaces can significantly enhance focus.

    8. Cognitive Behavioral Therapy (CBT)

    CBT can help you develop coping strategies for ADHD-related challenges, such as procrastination, impulsivity, and emotional regulation.

    9. Leverage ADHD-Friendly Technology

    Apps like Todoist, Notion, or Forest can assist with time management, task prioritization, and focus-building. Explore tools that align with your personal workflow.

    10. Foster Strong Social Connections

    Supportive relationships with family, friends, or ADHD communities can provide motivation, accountability, and understanding, reducing feelings of isolation.

    By implementing these strategies, individuals with ADHD can enhance their quality of life, productivity, and emotional well-being. Remember, each person’s ADHD experience is unique, so experiment with different approaches to find what works best for you!

    What has worked for you or someone you know? Share your experiences below!

  • Hoarding Disorder: A Looming National Crisis?

    Hoarding Disorder: A Looming National Crisis?

    A recent article on Medscape, Hoarding Disorder: A Looming National Crisis?, highlights the growing prevalence of hoarding disorder (HD) among older adults. While HD affects approximately 2% of the general population, studies suggest that prevalence may reach up to 6% among individuals over 70 years old.

    HD is characterized by persistent difficulty discarding possessions, even those with little to no monetary value. For individuals with HD, these items often provide a sense of security or serve as emotional reminders of the past. To outsiders, it’s difficult to understand why these possessions hold such deep significance, but for the person with HD, the items have profound sentimental value.

    Hoarding disorder is sometimes viewed as a subset of obsessive-compulsive disorder (OCD), but the overlap is not absolute. Many individuals with HD do not meet diagnostic criteria for OCD and often fail to respond to traditional OCD treatments. In my practice, I’ve come to conceptualize HD less as an extension of OCD and more as a personality-related condition influenced by environmental and psychological factors. For instance, many individuals with HD grew up in homes where similar behaviors were modeled. However, the precise causes of HD remain unclear.

    The consequences of HD are particularly concerning in older adults. The accumulation of clutter can pose significant safety risks, including fire hazards, tripping injuries, and even the potential for homelessness. These dangers were evident in a recent consult case where a medical team sought a psychiatric assessment of an elderly patient living in a severely cluttered home. Although the risks were undeniable, the individual did not meet criteria for psychiatric hospitalization. Even if hospitalization were an option, there is no FDA-approved treatment for HD at this time.

    The most evidence-based intervention we have for HD is cognitive-behavioral therapy (CBT), which requires sustained engagement over many weeks. Unfortunately, a key barrier is that many individuals with HD do not recognize the need for change or are reluctant to participate in therapy. This makes HD a uniquely challenging condition to address.

    Effective management of HD begins with education—helping patients understand the disorder, its risks, and the available treatment options. But education alone is not enough. We urgently need robust community support systems, including services to assist with clearing hazardous clutter and providing ongoing support to encourage treatment adherence.

    Inpatient psychiatric hospitalization, in my opinion, offers little benefit for HD. Instead, we need long-term, community-focused solutions. While policymakers often call for greater action to address mental health challenges, they frequently overlook the resource constraints faced by frontline providers. If we are to rise to this challenge, funding and systemic support must match the urgency of their rhetoric.

    HD is more than a personal struggle—it’s a public health issue with profound implications for individuals, families, and communities. As healthcare providers, we are ready to do more. Now, we need our leaders to step up and provide the resources to make that possible.

  • Buprenorphine vs. Methadone: The Battle for Opioid Use Disorder Treatment Supremacy

    Buprenorphine vs. Methadone: The Battle for Opioid Use Disorder Treatment Supremacy

    A recent study in JAMA compared the effectiveness of buprenorphine/naloxone versus methadone for opioid use disorder (OUD), focusing on treatment retention and mortality outcomes. The findings highlight important differences in these two mainstay treatments:

    1. Treatment Retention: Methadone demonstrated significantly higher retention rates compared to buprenorphine/naloxone. Retention is a critical metric, as staying in treatment reduces the risk of relapse and overdose. In flexible-dose studies, buprenorphine/naloxone patients were 37–40% more likely to discontinue treatment than methadone recipients. This aligns with its pharmacological profile, as methadone provides more consistent suppression of withdrawal symptoms.
    2. Mortality Rates: There were no significant differences in mortality risks between the two treatments, indicating both are comparably safe when provided in a supervised setting.
    3. Dosing Implications: Higher doses of buprenorphine (≥16 mg/day) were associated with better retention and reduced emergency care visits, suggesting dose adequacy is vital in achieving optimal outcomes. However, underdosing or rigid dosing protocols may limit buprenorphine’s effectiveness in real-world settings.
    4. Practical Considerations: Methadone requires daily visits to specialized clinics, which can be a barrier to care for some patients. In contrast, buprenorphine/naloxone can often be prescribed in primary care settings, improving accessibility.

    The choice between methadone and buprenorphine/naloxone should be individualized, considering patient preferences, clinical circumstances, and potential barriers to adherence. These findings underscore the need for flexible treatment options tailored to the patient population.

  • Tragic Loss of United Healthcare CEO Shines Spotlight on Insurance Denials

    Tragic Loss of United Healthcare CEO Shines Spotlight on Insurance Denials

    I would never condone violence against anyone, and the loss of any life in such a manner is a profound tragedy. That said, this event has sparked a critical and necessary conversation about the devastating impact of insurance companies denying claims for essential healthcare.

    Far too often, people feel abandoned by these companies during their most vulnerable moments, when their lives are quite literally on the line. As a healthcare provider, I’ve had countless experiences fighting with insurance companies for additional days of coverage for acutely suicidal patients who were clearly not ready for discharge. Each time, I was left with the unshakable impression that the priority was not patient care but finding any justification to deny coverage, regardless of the circumstances.

    This systemic disregard for the value of human life in favor of profit leaves a lasting impression—one that is deeply unsettling. It’s a stark reminder of how broken the system is when patients’ lives, and the quality of care they receive, are treated as secondary to financial interests.

  • Ondansetron as an Augmentative Treatment for OCD: What Does the Evidence Say?

    Ondansetron as an Augmentative Treatment for OCD: What Does the Evidence Say?

    Obsessive-Compulsive Disorder (OCD) is often treated with selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT). Despite these interventions, many patients experience only partial relief. This has led researchers to explore augmentation strategies, including the addition of ondansetron, a serotonin 5-HT3 receptor antagonist.

    Mechanism of Action

    • 5-HT3 antagonism: Ondansetron modulates serotonin in a different way compared to SSRIs. Preclinical studies suggest it may reduce compulsive behaviors by altering serotoninergic and dopaminergic activity in brain regions implicated in OCD, such as the orbitofrontal cortex and basal ganglia.

    Evidence from Clinical Trials

    1. Shavakhi et al. (2014):
      • Design: Double-blind, randomized controlled trial (RCT).
      • Participants: 40 patients with OCD who had a partial response to fluoxetine.
      • Intervention: Fluoxetine (20–40 mg/day) + placebo vs. fluoxetine + ondansetron (4 mg/day).
      • Results: Significant improvement in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores with ondansetron by week 8.
      • Conclusion: Ondansetron was well-tolerated and effective as an adjunctive treatment.
    2. Haghighi et al. (2013):
      • Design: Similar double-blind RCT with 60 patients on fluvoxamine (100–200 mg/day).
      • Results: Patients receiving ondansetron (4 mg/day) showed greater reductions in Y-BOCS scores than those on placebo.
      • Conclusion: Ondansetron enhanced the anti-obsessional effects of SSRIs.
    3. Meta-Analysis (Emerging Data):
      • While limited RCTs exist, early analyses highlight ondansetron’s promise, particularly in SSRI partial responders.

    Practical Considerations

    • Dosage: Typically 4 mg/day in studies.
    • Tolerability: Generally well-tolerated, with mild side effects like headache and dizziness reported in trials.
    • Population: Evidence supports its use in patients with partial response to SSRIs.

    Current Limitations

  • Sample Sizes: Studies to date have small cohorts, limiting generalizability.

  • Duration: Most trials span 8–12 weeks, leaving long-term efficacy unclear.

  • Mechanistic Data: While promising, the precise mechanisms remain speculative.

    • Clinical Takeaway

    Ondansetron appears to be a safe and potentially effective augmentation strategy for patients with OCD who have not achieved full remission on SSRIs alone. While more robust data are needed, its unique mechanism and tolerability make it an intriguing option in treatment-resistant cases.

  • Buprenorphine and Psychosis: Unraveling the Risks of Abrupt Discontinuation

    Buprenorphine and Psychosis: Unraveling the Risks of Abrupt Discontinuation

    This post is inspired by a real case from my practice involving a patient with no significant past psychiatric history but a strong history of substance use, including opioids and cocaine. The patient had been on buprenorphine maintenance therapy for several decades, providing stability in their recovery. However, following an abrupt discontinuation of buprenorphine, the patient developed acute psychotic symptoms. This case highlights an uncommon but important phenomenon clinicians should be aware of when managing buprenorphine discontinuation, especially in individuals with a history of substance use.

    Emerging evidence suggests that abrupt discontinuation of buprenorphine may induce psychosis in some individuals, though this appears to be a relatively uncommon occurrence.

    Documented Cases

    • New-onset psychotic symptoms have been reported after sudden cessation of buprenorphine in patients with no prior psychosis.
    • Common symptoms include auditory hallucinations, paranoid ideation, and delusions of reference.
    • Psychotic symptoms typically emerge within days to weeks after discontinuation.

    Potential Mechanisms

    1. Loss of buprenorphine’s antipsychotic effects through kappa-opioid receptor antagonism.
    2. Interaction between neurobiological vulnerabilities and the stress of withdrawal.
    3. Possible unmasking of latent psychotic disorders.

    Risk Factors

    • History of substance use.
    • Early adverse life events.
    • Underlying psychiatric conditions (e.g., bipolar disorder).

    Outcomes and Management

    • Symptoms may resolve in weeks to months, though some cases persist longer.
    • Reintroduction of buprenorphine has led to symptom remission in some cases, suggesting a causal relationship.
    • Gradual tapering of buprenorphine might mitigate this risk, though more research is needed.

    Clinical Implications

    Clinicians should remain vigilant when discontinuing buprenorphine, especially in individuals with risk factors for psychosis. A gradual tapering strategy is recommended to reduce potential risks, though further studies are necessary to guide best practices.

    Understanding this phenomenon highlights the importance of individualized care when managing buprenorphine discontinuation in vulnerable populations.